Literature DB >> 18509810

TCI : Target controlled infusion, or totally confused infusion? Call for an optimised population based pharmacokinetic model for propofol.

Mats Enlund1.   

Abstract

Different pharmacokinetic models for target controlled infusion (TCI) of propofol are available in the recently launched open TCI systems. There is also a compelling choice to work with either plasma- or effect-site targets. Knowledge about the clinical consequences of different alternatives is of importance. We aimed to illustrate the potential differences in the actual drug delivery/output between three present commercially available and clinically used pharmacokinetic models: the original Marsh model, which is also implemented in the Diprifusor, the "modified Marsh-" and the Schnider models. Simulations were made in the TivaTrainer program (eurosiva.com). Firstly, our standard plasma target regimen was simulated, and secondly an effect-site target of 3.5 microg/mL was chosen. Thirdly, real infusors were used for measuring the time to reach defined predicted effect-site concentrations when aiming at a plasma target of 6 microg/mL. Identical patient characteristics were used in all simulations: male, 170 cm, 70 kg, 40 years of age. Resulting predicted effect-site peak concentrations, and used bolus doses were recorded, as were the resulting plasma over-shoot, and time frames. The plasma target regimen gave predicted effect-site peaks in the different models ranging from 3.6 to 7.2 microg/mL, reached after 2(3/4) to 4 minutes. To reach the same effect-site target, the three models used bolus doses ranging from 68 to 150 mg given during 22 to 46 seconds. The predicted plasma concentration over-shoots varied from 5.0 to 13.4 microg/mL. There were obvious differences between the models in the time taken to reach defined effect-site concentrations. We observed clinically significant different results between the models. The choice of model will make a difference for the patient. To eliminate confusion - not necessarily to improve precision - we call for an optimised population based pharmacokinetic model for propofol - a consensus model!

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509810     DOI: 10.3109/2000-1967-222

Source DB:  PubMed          Journal:  Ups J Med Sci        ISSN: 0300-9734            Impact factor:   2.384


  5 in total

1.  Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusions.

Authors:  Johan Francois Coetzee
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

Review 2.  [Target-controlled infusion. Clinical relevance and special features when using pharmacokinetic models].

Authors:  H Ihmsen; S Schraag; S Kreuer; J Bruhn; S Albrecht
Journal:  Anaesthesist       Date:  2009-07       Impact factor: 1.041

3.  Bi-spectral index, entropy and predicted plasma propofol concentrations with target controlled infusions in Indian patients.

Authors:  Goverdhan D Puri; Preethy J Mathew; J Sethu Madhavan; Harihar V Hegde; Andreas Fiehn
Journal:  J Clin Monit Comput       Date:  2011-10-01       Impact factor: 2.502

4.  Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion.

Authors:  Wan Mohd Nazaruddin Wan Hassan; Hai Siang Tan; Rhendra Hardy Mohamed Zaini
Journal:  Malays J Med Sci       Date:  2018-02-28

5.  The Use of Middle Latency Auditory Evoked Potentials (MLAEP) as Methodology for Evaluating Sedation Level in Propofol-Drug Induced Sleep Endoscopy (DISE) Procedure.

Authors:  Michele Arigliani; Domenico M Toraldo; Enrico Ciavolino; Caterina Lattante; Luana Conte; Serena Arima; Caterina Arigliani; Antonio Palumbo; Michele De Benedetto
Journal:  Int J Environ Res Public Health       Date:  2021-02-20       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.